SANA BIOTECHNOLOGY INC (SANA) Stock Price, Quote, News and Overview
NASDAQ:SANA - Nasdaq - US7995661045 - Common Stock - Currency: USD
SANA Quote, Performance and Key Statistics
2.61
-0.15 (-5.43%)
The current stock price of SANA is 2.61 USD. In the past month the price increased by 33.16%. In the past year, price decreased by -52.63%.
SANA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.04 | 327.31B | ||
| AMGN | AMGEN INC | 13.94 | 155.58B | ||
| GILD | GILEAD SCIENCES INC | 14.02 | 134.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.5 | 55.03B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.38B | ||
| ARGX | ARGENX SE - ADR | 94.29 | 33.10B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.32 | 26.73B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.61B | ||
| NTRA | NATERA INC | N/A | 23.47B | ||
| INSM | INSMED INC | N/A | 18.70B | ||
| BIIB | BIOGEN INC | 8.03 | 18.62B |
Related stock screener links
About SANA
Company Profile
Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. The company is headquartered in Seattle, Washington and currently employs 194 full-time employees. The company went IPO on 2021-02-04. The company is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. The company develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The firm is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.
Company Info
SANA BIOTECHNOLOGY INC
188 East Blaine Street, Suite 400
Seattle WASHINGTON 98102 US
CEO: Steven D. Harr
Employees: 328
Phone: 12067017914
SANA BIOTECHNOLOGY INC / SANA FAQ
What is the stock price of SANA BIOTECHNOLOGY INC today?
The current stock price of SANA is 2.61 USD. The price decreased by -5.43% in the last trading session.
What is the ticker symbol for SANA BIOTECHNOLOGY INC stock?
The exchange symbol of SANA BIOTECHNOLOGY INC is SANA and it is listed on the Nasdaq exchange.
On which exchange is SANA stock listed?
SANA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SANA BIOTECHNOLOGY INC stock?
14 analysts have analysed SANA and the average price target is 9.52 USD. This implies a price increase of 264.75% is expected in the next year compared to the current price of 2.61. Check the SANA BIOTECHNOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SANA BIOTECHNOLOGY INC worth?
SANA BIOTECHNOLOGY INC (SANA) has a market capitalization of 588.71M USD. This makes SANA a Small Cap stock.
How many employees does SANA BIOTECHNOLOGY INC have?
SANA BIOTECHNOLOGY INC (SANA) currently has 328 employees.
What are the support and resistance levels for SANA BIOTECHNOLOGY INC (SANA) stock?
SANA BIOTECHNOLOGY INC (SANA) has a support level at 2.51 and a resistance level at 2.82. Check the full technical report for a detailed analysis of SANA support and resistance levels.
Should I buy SANA BIOTECHNOLOGY INC (SANA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SANA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SANA, evaluating the profitability, health, valuation and growth aspects
- SANA BIOTECHNOLOGY INC (SANA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SANA BIOTECHNOLOGY INC (SANA) Sales and EPS estimates to see what analysts future expectations are.
- SANA BIOTECHNOLOGY INC (SANA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SANA BIOTECHNOLOGY INC (SANA) Insider and Institutional Ownership to learn about the owners and their transactions.
- SANA BIOTECHNOLOGY INC (SANA) Stock Chart to make your own analysis
- SANA BIOTECHNOLOGY INC (SANA) Latest news and press-releases to stay up to date.
Does SANA BIOTECHNOLOGY INC (SANA) stock pay dividends?
SANA does not pay a dividend.
When does SANA BIOTECHNOLOGY INC (SANA) report earnings?
SANA BIOTECHNOLOGY INC (SANA) will report earnings on 2025-08-06, after the market close.
What is the Price/Earnings (PE) ratio of SANA BIOTECHNOLOGY INC (SANA)?
SANA BIOTECHNOLOGY INC (SANA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.88).
What is the Short Interest ratio of SANA BIOTECHNOLOGY INC (SANA) stock?
The outstanding short interest for SANA BIOTECHNOLOGY INC (SANA) is 21.53% of its float. Check the ownership tab for more information on the SANA short interest.
SANA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to SANA. When comparing the yearly performance of all stocks, SANA is a bad performer in the overall market: 85.1% of all stocks are doing better.
SANA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SANA. SANA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SANA Financial Highlights
Over the last trailing twelve months SANA reported a non-GAAP Earnings per Share(EPS) of -0.88. The EPS increased by 40.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -46.84% | ||
| ROE | -99.81% | ||
| Debt/Equity | 0 |
SANA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to SANA. The Buy consensus is the average rating of analysts ratings from 14 analysts.